LaunXP will pay Apollomics $10m upfront within 60 days of the agreement date. Apollomics is also qualified for potential ...

If you have metastatic non-small-cell lungcancer (NSCLC), you might wonder if the treatment plan that your doctor recommended is the best one for you. Metastatic NSCLC is “stage IV” or ...

Apollomics (APLM) and LaunXP International, an affiliate of LaunXP Biomedical, announced that the parties have entered into an agreement for ...

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...

Emerging data suggest that SBRT may be comparable with surgery for definitive treatment of stage I NSCLC in certain patients. When is one approach preferred and in whom?

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...

80% of lung cancer is something called nonsmall cell lung cancer. So where are we today in terms of diagnosis, treatment, and what does the future hold? So to help answer these questions ...

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for ...

Real-world experiences and treatments for lung cancer and head & neck cancer were shared at scientific conferences entitled ...